Compare Intuit Inc. (INTU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Intuit Inc. trades at $303.37 (market cap $81.21B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Intuit Inc. is far larger — about 37.9× Recursion Pharmaceuticals Inc's market cap, and Intuit Inc. pays a 1.82% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| INTU | RXRX | |
|---|---|---|
Market Cap | $81.21B | $2.14B |
Volume | 5,165,806 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $683.39 | $6.79 |
52-Week Low | $255.07 | $2.84 |
Typical Hold Time | 66 Days | 22 Days |
Enterprise Value | $82.43B | $1.66B |
Dividend Yield | 1.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $303.88, up 4.85% today, with strong fundamental performance including 21.3% net income margin and consistent earnings beats. The stock shows bullish technical momentum with resistance at $308 and support at $293. Recent financials reveal robust revenue growth from $18.8B in 2025 to projected $21.4B in 2026, though legal challenges from class action lawsuits present near-term headwinds.
Outlook remains positive with analyst consensus target of $379.68 (25% upside), driven by AI integration and QuickBooks monetization. Key risks include litigation overhang and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, supporting long-term growth trajectory despite technical overbought signals.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
